Cargando…
Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming
The impact of EGFR-mutant NSCLC precision therapy is limited by acquired resistance despite initial excellent response. Classic studies of EGFR-mutant clinical resistance to precision therapy were based on tumor rebiopsies late during clinical tumor progression on therapy. Here, we characterized a n...
Autores principales: | Thiagarajan, Praveena S., Wu, Xiaoliang, Zhang, Wei, Shi, Ivy, Bagai, Rakesh, Leahy, Patrick, Feng, Yan, Veigl, Martina, Lindner, Daniel, Danielpour, David, Yin, Lihong, Rosell, Rafael, Bivona, Trever G., Zhang, Zhenfeng, Ma, Patrick C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347670/ https://www.ncbi.nlm.nih.gov/pubmed/27852038 http://dx.doi.org/10.18632/oncotarget.13307 |
Ejemplares similares
-
Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021) -
AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015) -
Chemically induced reprogramming to reverse cellular aging
por: Yang, Jae-Hyun, et al.
Publicado: (2023) -
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
por: Lin, Luping, et al.
Publicado: (2012) -
Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)